WY-14643 (Pirinixic Acid): Advanced Insights into PPARα/γ Agonism and Liver Regeneration

Introduction

WY-14643, also known as Pirinixic Acid, has long served as a benchmark PPARα agonist in the study of lipid metabolism regulation, inflammation, and metabolic disorder research. However, recent advances have revealed new dimensions to its action, including nuanced effects on dual PPARα/γ signaling and a surprising role in liver regeneration. This article delivers an in-depth, research-driven analysis of WY-14643, integrating mechanistic insights, experimental strategies, and the latest breakthroughs. Building on—but distinctly diverging from—previous overviews of systems-level PPARα agonism and practical workflow guides, we focus on the molecular interplay between PPAR signaling and hepatic tissue remodeling, providing a new cornerstone for metabolic and regenerative research.

WY-14643 (Pirinixic Acid): Structure, Selectivity, and Formulation

WY-14643 (SKU: A4305), available from APExBIO, is a potent, selective PPARα agonist for metabolic research. Its IC₅₀ for human PPARα is 10.11 µM, making it highly effective for both in vitro and in vivo studies. Aliphatic α-substitution increases its dual agonistic activity at PPARγ, yielding balanced dual PPARα/γ agonists that expand its utility in dissecting complex metabolic pathways. WY-14643 is supplied as a solid, water-insoluble compound, readily soluble in DMSO and ethanol, and is intended solely for scientific research applications. For detailed specifications and ordering, see the WY-14643 (Pirinixic Acid) product page.

Mechanism of Action of WY-14643 (Pirinixic Acid)

PPARα Activation and Beyond

WY-14643 functions predominantly as a selective agonist of peroxisome proliferator-activated receptor alpha (PPARα), a nuclear receptor that orchestrates genes involved in lipid oxidation, energy homeostasis, and inflammation. Upon ligand binding, PPARα forms heterodimers with RXR and binds to PPAR response elements (PPREs) within target gene promoters, upregulating pathways central to fatty acid catabolism and anti-inflammatory responses.

Dual PPARα/γ Agonism: Expanding the Horizons

Structural modifications—specifically at the aliphatic α-position—endow WY-14643 with partial PPARγ agonist activity, creating a platform for dual PPARα/γ agonist action. This balanced activity is especially valuable for probing the intersection of lipid and glucose metabolism, as PPARγ influences adipogenesis and insulin sensitivity. Such duality positions WY-14643 as a bridge compound for studying metabolic syndrome, NAFLD, and diabetes models.

WY-14643 in Modulation of the PPAR Signaling Pathway and Inflammation

The ability of WY-14643 to regulate the PPAR signaling pathway has made it indispensable in the study of metabolic and inflammatory diseases. Notably, it suppresses TNF-α mediated inflammation by downregulating VCAM-1 expression and reducing monocyte adhesion in endothelial cells, supporting its profile as an anti-inflammatory agent in endothelial cells. In hepatic tissue, moderate elevation of TNFα mRNA via Kupffer cell activation suggests a role in immune modulation and tissue remodeling.

WY-14643 and Liver Regeneration: The YAP-TEAD Axis

From Metabolic Regulation to Tissue Remodeling

While previous reviews have highlighted the metabolic and immunomodulatory effects of WY-14643 (see immunometabolic perspectives), emerging studies have uncovered its pivotal role in liver regeneration—a dimension largely absent from earlier coverage.

In a landmark investigation by Wang et al. (YAP-TEAD mediates peroxisome proliferator-activated receptor α induced hepatomegaly and liver regeneration in mice), mice administered WY-14643 exhibited significant hepatomegaly and enhanced hepatic regeneration after partial hepatectomy. Mechanistically, this effect was shown to be dependent not only on PPARα activation but also on the downstream YAP-TEAD transcriptional module. Genetic ablation of YAP (Yes-associated protein) or pharmacological disruption of YAP-TEAD interaction abrogated the proliferative and regenerative effects of WY-14643, confirming a dual requirement for both PPARα and YAP-TEAD signaling. This mechanistic insight provides a new paradigm for understanding how selective PPARα agonists mediate tissue remodeling beyond canonical metabolic endpoints.

Experimental Design and Key Findings

• Model: C57BL/6 and genetically modified mice (Pparafl/fl, PparaΔHep, Yapfl/fl, and Yap∆Hep) were used to dissect the roles of PPARα and YAP in liver response to WY-14643.
• Dosing: 100 mg/kg/day WY-14643 by intraperitoneal injection for up to 10 days.
• Endpoints: Liver weight, serum biochemistry (ALT, AST, ALP, ALB, TBA, TBIL), histological assessment (H&E, KI67, β-catenin), and gene expression (qPCR).
• Findings: WY-14643 induced hepatomegaly and promoted hepatic proliferation, both of which were abrogated by YAP deficiency or YAP-TEAD inhibition. PPARα activation alone was insufficient for full regenerative response in the absence of YAP-TEAD activity.

This mechanism was elucidated in a seminal study by Wang et al. (see above, summarized in this article).

Comparative Analysis with Alternative PPAR Agonists and Experimental Approaches

Most existing literature, such as protocol-centric reviews, focuses on the practical implementation of WY-14643 in dissecting PPAR signaling and troubleshooting experimental workflows. While these resources are invaluable for laboratory optimization, they often overlook the broader implications of dual PPARα/γ agonism and the intersection with regenerative biology.

Alternative compounds, such as fenofibrate and GW7647, display PPARα selectivity but lack the dual activity and regenerative synergy observed with WY-14643. Furthermore, their inability to robustly engage YAP-TEAD pathways limits their application in tissue repair models. This highlights the unique experimental positioning of WY-14643, especially for investigations requiring simultaneous modulation of metabolic and regenerative processes.

Advanced Applications: Beyond Metabolism—WY-14643 in Regenerative and Translational Research

Insulin Sensitivity Enhancement and Metabolic Disease Models

In animal studies, oral administration of WY-14643 at 3 mg/kg/day for two weeks in high fat-fed rats led to significant reductions in plasma glucose, triglycerides, leptin, and muscle triglycerides, alongside decreased visceral fat and liver triglyceride content. Notably, whole-body insulin sensitivity enhancement was achieved without concomitant weight gain. These findings support the use of WY-14643 as a model compound in metabolic disorder research, particularly for exploring the interface of lipid metabolism regulation and insulin signaling.

Hepatic Regeneration and Disease Modeling

The demonstration that WY-14643 can activate the YAP-TEAD axis to drive liver regeneration unlocks new avenues for studying tissue repair, fibrosis, and cell proliferation dynamics. This distinguishes WY-14643 from other PPAR modulators and positions it as a valuable probe for investigating the interplay between metabolic signaling and regenerative medicine.

Anti-Inflammatory Agent in Endothelial Cells

WY-14643's capacity to suppress TNF-α-induced VCAM-1 expression and monocyte adhesion in endothelial cells further broadens its application spectrum—enabling the dissection of vascular inflammation and atherosclerosis mechanisms. This anti-inflammatory property complements its metabolic effects, allowing for holistic modeling of cardio-metabolic diseases.

Experimental Considerations and Best Practices

Given its insolubility in water, WY-14643 should be dissolved in DMSO (≥16.2 mg/mL) or ethanol (≥48.8 mg/mL with ultrasonic assistance) for cell culture and animal studies. Solutions are best prepared fresh and used short-term, with storage of the solid at -20°C. Researchers are advised to titrate concentrations based on the model system—250 μM for in vitro anti-inflammatory assays, and up to 100 mg/kg in rodent models for regenerative effects.

For implementation insights and troubleshooting tips, see the technical guide on optimizing cell assays with WY-14643. This complements the present article by addressing workflow reliability, while our focus remains on mechanistic and translational frontiers.

Content Differentiation: A New Paradigm for WY-14643 Research

Unlike prior reviews that emphasize the compound’s role in metabolic and immunometabolic regulation or laboratory optimization, this article pioneers a molecular systems approach—interrogating the convergence of PPARα/γ dual agonism, YAP-TEAD signaling, and regenerative biology. By integrating recent mechanistic discoveries with practical guidance, we offer a comprehensive reference for researchers seeking to leverage WY-14643 in advanced metabolic and regenerative studies.

Conclusion and Future Outlook

WY-14643 (Pirinixic Acid) remains the gold standard selective PPARα agonist for metabolic research, but its utility now spans far beyond canonical lipid metabolism regulation. The compound’s unique ability to modulate both PPARα/γ and YAP-TEAD pathways positions it at the forefront of translational research in metabolism, inflammation, and tissue regeneration. As regenerative medicine and systems biology converge, WY-14643 will continue to unlock new mechanistic insights and therapeutic applications.

For researchers aiming to advance the frontiers of metabolic and regenerative science, WY-14643 (Pirinixic Acid) from APExBIO offers unmatched performance and versatility.